Related Experiment Videos
Isolated limb perfusion: what is the evidence for its use?
Eva M Noorda1, Bart C Vrouenraets, Omgo E Nieweg
1The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands. em_noorda@yahoo.com.
Annals of Surgical Oncology
|August 18, 2004
Summary
Isolated limb perfusion (ILP) is indicated for unresectable melanoma and soft tissue sarcoma (STS) of the limbs. While not recommended for primary melanoma, ILP shows promise for recurrent melanoma and is the most effective limb-sparing treatment for unresectable STS.
Area of Science:
- Oncology
- Surgical Oncology
- Evidence-Based Medicine
Background:
- Assessing the efficacy of isolated limb perfusion (ILP) using the best available evidence.
- Evaluating ILP for melanoma and soft tissue sarcoma (STS) of the limbs.
Purpose of the Study:
- To determine the optimal use of isolated limb perfusion (ILP) based on current evidence.
- To analyze the effectiveness of ILP in treating limb melanomas and soft tissue sarcomas.
Main Methods:
- Systematic review of evidence-based medicine principles.
- Analysis of studies on isolated limb perfusion (ILP) for melanoma and STS.
- Evaluation of evidence levels (1b, 2b, 3, 4) for different ILP applications.
Main Results:
- Adjuvant ILP for primary melanoma is not recommended due to limited benefit and no survival increase (Level 1b).
- Prophylactic ILP for recurrent melanoma shows a trend towards decreased recurrence but no survival benefit (Level 2b).
- Therapeutic ILP is indicated for unresectable melanoma (Level 3-4) and offers high limb salvage rates with low complications for unresectable STS (Level 3).
Conclusions:
- Isolated limb perfusion (ILP) is indicated for unresectable locoregional melanoma and STS of the limbs.
- Prophylactic ILP may impact micrometastatic disease in recurrent limb melanoma.
- ILP is the most effective neoadjuvant limb-sparing treatment for unresectable STS, despite a lack of randomized studies.